“Lipid Profile in People Starting Antiretroviral Therapy With Efavirenz or Dolutegravir Based Regimens from a Reference Center in Brazil: A Cohort Study”. Research, Society and Development, vol. 11, no. 5, Apr. 2022, p. e55811528662, https://doi.org/10.33448/rsd-v11i5.28662.